Literature DB >> 11244258

Improved survival in small pancreatic cancer.

D Pantalone1, I Ragionieri, G Nesi.   

Abstract

BACKGROUND: Although the incidence of pancreatic cancer is relatively low compared with other tumors (2.4%), the death rate is high. Tumor detection and treatment at an early stage is necessary to improve the poor prognosis of patients, as is demonstrated by some reports showing a 5-year survival rate varying between 19 and 41% for patients undergoing radical pancreatectomy with the highest survival in patients with small tumors.
METHODS: In our study we retrospectively reviewed the histologic and demographic data of 596 patients who were admitted to the surgical units of the Careggi Hospital (University of Florence-AOC of Florence) between 1988 and 1994 with the incoming diagnosis of pancreatic cancer.
RESULTS: Results are reported as the mean +/- standard deviation. The postoperative survival rate was calculated by the Kaplan-Meier method and statistical analysis was performed by the log rank test (significance p < 0.05). 247 patients had surgery, 110 with a curative intent. Postoperative mortality was 5.45%. The crude 5-year survival rate for patients who underwent curative surgery was 16.36% (18 patients), but for patients with small lesions confined to the pancreas (T1N0M0, 29 patients) this was even 31.03% (9 patients; p < 0.01, chi2 test).
CONCLUSIONS: Our results indicate that it seems reasonable to consider these cancers as 'small', with survival reported in literature from 35 to 41%, so they probably represent the only curable condition at the present time.

Entities:  

Mesh:

Year:  2001        PMID: 11244258     DOI: 10.1159/000050095

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  7 in total

1.  The evaluation of duct-to-mucosal pancreaticojejunostomy in pancreaticoduodenectomy.

Authors:  Masaji Tani; Hironobu Onishi; Hiroyuki Kinoshita; Manabu Kawai; Masaki Ueno; Takashi Hama; Kazuhisa Uchiyama; Hiroki Yamaue
Journal:  World J Surg       Date:  2005-01       Impact factor: 3.352

2.  Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis.

Authors:  Renata Talar-Wojnarowska; Anita Gasiorowska; Beata Smolarz; Hanna Romanowicz-Makowska; Janusz Strzelczyk; Adam Janiak; Andrzej Kulig; Ewa Malecka-Panas
Journal:  Int J Gastrointest Cancer       Date:  2005

3.  Long-term survival and prognostic indicators in small (<or=2 cm) pancreatic cancer.

Authors:  Supot Pongprasobchai; Rahul Pannala; Thomas C Smyrk; William Bamlet; Suresh Pitchumoni; Andrei Ougolkov; Mariza de Andrade; Gloria M Petersen; Suresh T Chari
Journal:  Pancreatology       Date:  2008-10-13       Impact factor: 3.996

4.  A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer.

Authors:  Nobuaki Suzuki; Shoichi Hazama; Tomio Ueno; Hiroto Matsui; Yoshitaro Shindo; Michihisa Iida; Kiyoshi Yoshimura; Shigefumi Yoshino; Kazuyoshi Takeda; Masaaki Oka
Journal:  J Immunother       Date:  2014-01       Impact factor: 4.456

5.  Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma.

Authors:  Kenjiro Kimura; Ryosuke Amano; Bunzo Nakata; Sadaaki Yamazoe; Keiichiro Hirata; Akihiro Murata; Kotaro Miura; Kohei Nishio; Toshiki Hirakawa; Masaichi Ohira; Kosei Hirakawa
Journal:  World J Surg Oncol       Date:  2014-11-27       Impact factor: 2.754

Review 6.  The bidirectional interation between pancreatic cancer and diabetes.

Authors:  Junhui Li; Gang Cao; Qingyong Ma; Han Liu; Wei Li; Liang Han
Journal:  World J Surg Oncol       Date:  2012-08-24       Impact factor: 2.754

7.  Clinicopathological aspects of 542 cases of pancreatic cancer: a special emphasis on small pancreatic cancer.

Authors:  Kee Wook Jung; Myung Hwan Kim; Tae Yoon Lee; Seunghyun Kwon; Hyoung Chul Oh; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee
Journal:  J Korean Med Sci       Date:  2007-09       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.